PMID- 31821351
OWN - NLM
STAT- MEDLINE
DCOM- 20200331
LR  - 20200331
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 14
IP  - 12
DP  - 2019
TI  - RBM3 and CIRP expressions in targeted temperature management treated cardiac 
      arrest patients-A prospective single center study.
PG  - e0226005
LID - 10.1371/journal.pone.0226005 [doi]
LID - e0226005
AB  - BACKGROUND: Management of cardiac arrest patients includes active body 
      temperature control and strict prevention of fever to avoid further neurological 
      damage. Cold-shock proteins RNA-binding motif 3 (RBM3) and cold inducible 
      RNA-binding protein (CIRP) expressions are induced in vitro in response to 
      hypothermia and play a key role in hypothermia-induced neuroprotection. 
      OBJECTIVE: To measure gene expressions of RBM3, CIRP, and inflammatory biomarkers 
      in whole blood samples from targeted temperature management (TTM)-treated 
      post-cardiac arrest patients for the potential application as clinical biomarkers 
      for the efficacy of TTM treatment. METHODS: A prospective single center trial 
      with the inclusion of 22 cardiac arrest patients who were treated with TTM (33 degrees C 
      for 24 hours) after ROSC was performed. RBM3, CIRP, interleukin 6 (IL-6), 
      monocyte chemotactic protein 1 (MCP-1), and inducible nitric oxide synthase 
      (iNOS) mRNA expressions were quantified by RT-qPCR. Serum RBM3 protein 
      concentration was quantified using an enzyme-linked immunosorbent assay (ELISA). 
      RESULTS: RBM3 mRNA expression was significantly induced in post-cardiac arrest 
      patients in response to TTM. RBM3 mRNA was increased 2.2-fold compared to before 
      TTM. A similar expression kinetic of 1.4-fold increase was observed for CIRP 
      mRNA, but did not reached significancy. Serum RBM3 protein was not increased in 
      response to TTM. IL-6 and MCP-1 expression peaked after ROSC and then 
      significantly decreased. iNOS expression was significantly increased 24h after 
      return of spontaneous circulation (ROSC) and TTM. CONCLUSIONS: RBM3 is 
      temperature regulated in patients treated with TTM after CA and ROSC. RBM3 is a 
      possible biomarker candidate to ensure the efficacy of TTM treatment in 
      post-cardiac arrest patients and its pharmacological induction could be a 
      potential future intervention strategy that warrants further research.
FAU - Rosenthal, Lisa-Maria
AU  - Rosenthal LM
AUID- ORCID: 0000-0003-4083-1186
AD  - Dept. for Congenital Heart Disease/Pediatric Cardiology, Deutsches Herzzentrum 
      Berlin, Berlin, Germany.
AD  - Berlin Institute of Health, Berlin, Germany.
FAU - Leithner, Christoph
AU  - Leithner C
AD  - Dept. of Neurology, Charite Universtitatsmedizin Berlin, Berlin, Germany.
FAU - Tong, Giang
AU  - Tong G
AD  - Dept. for Congenital Heart Disease/Pediatric Cardiology, Deutsches Herzzentrum 
      Berlin, Berlin, Germany.
FAU - Streitberger, Kaspar Josche
AU  - Streitberger KJ
AD  - Berlin Institute of Health, Berlin, Germany.
AD  - Dept. of Neurology, Charite Universtitatsmedizin Berlin, Berlin, Germany.
FAU - Krech, Jana
AU  - Krech J
AD  - Dept. for Congenital Heart Disease/Pediatric Cardiology, Deutsches Herzzentrum 
      Berlin, Berlin, Germany.
FAU - Storm, Christian
AU  - Storm C
AD  - Dept. of Internal Medicine, Nephrology and Intensive Care, Charite 
      Universitatsmedizin Berlin, Berlin, Germany.
FAU - Schmitt, Katharina Rose Luise
AU  - Schmitt KRL
AUID- ORCID: 0000-0003-0860-1137
AD  - Dept. for Congenital Heart Disease/Pediatric Cardiology, Deutsches Herzzentrum 
      Berlin, Berlin, Germany.
AD  - Dept. for Pediatric Cardiology, Charite Universitatsmedizin Berlin, Berlin, 
      Germany.
AD  - DHZK (German Centre for Cardiovascular Research), Berlin, Germany.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20191210
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Biomarkers)
RN  - 0 (CCL2 protein, human)
RN  - 0 (CIRBP protein, human)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Interleukin-6)
RN  - 0 (RBM3 protein, human)
RN  - 0 (RNA-Binding Proteins)
RN  - EC 1.14.13.39 (NOS2 protein, human)
RN  - EC 1.14.13.39 (Nitric Oxide Synthase Type II)
SB  - IM
MH  - Aged
MH  - Biomarkers/blood
MH  - Blood Gas Analysis
MH  - Body Temperature
MH  - Chemokine CCL2/genetics/metabolism
MH  - Female
MH  - Heart Arrest/*diagnosis/therapy
MH  - Humans
MH  - *Hypothermia, Induced
MH  - Interleukin-6/genetics/metabolism
MH  - Male
MH  - Middle Aged
MH  - Nitric Oxide Synthase Type II/genetics/metabolism
MH  - Prospective Studies
MH  - RNA-Binding Proteins/blood/genetics/*metabolism
PMC - PMC6903712
COIS- The authors have declared that no competing interests exist.
EDAT- 2019/12/11 06:00
MHDA- 2020/04/01 06:00
PMCR- 2019/12/10
CRDT- 2019/12/11 06:00
PHST- 2019/06/04 00:00 [received]
PHST- 2019/11/17 00:00 [accepted]
PHST- 2019/12/11 06:00 [entrez]
PHST- 2019/12/11 06:00 [pubmed]
PHST- 2020/04/01 06:00 [medline]
PHST- 2019/12/10 00:00 [pmc-release]
AID - PONE-D-19-15832 [pii]
AID - 10.1371/journal.pone.0226005 [doi]
PST - epublish
SO  - PLoS One. 2019 Dec 10;14(12):e0226005. doi: 10.1371/journal.pone.0226005. 
      eCollection 2019.